Clinical trial
ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)
NCT00041509 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00041509 |
|---|---|
| Title | ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) |
| Official title | ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty |
| Acronym | TEMPEST |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthroplasty |
| Intervention type | Drug |
| Interventions | SB-424323, Placebo |
| Enrollment | 343 |
| Start date | Jan 1, 2002 |
| Primary completion | May 1, 2003 |
| Completion | May 1, 2003 |
| First posted | Jul 12, 2002 |
| Last update posted | May 30, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: